88 related articles for article (PubMed ID: 10442358)
1. Hospitalization for 5-FU toxicity in metastatic colorectal cancer: incidence and cost.
Oster G
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):41. PubMed ID: 10442358
[TBL] [Abstract][Full Text] [Related]
2. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer.
Delea TE; Vera-Llonch M; Edelsberg JS; McGarry L; Anton S; Ulcickas-Yood M; Oster G
Value Health; 2002; 5(1):35-43. PubMed ID: 11873382
[TBL] [Abstract][Full Text] [Related]
3. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
[TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of chemotherapy regimen fluorouracil/leucovorin/oxaliplatin compared with fluorouracil/leucovorin in treating advanced colorectal cancer.
Chen ML; Fang CH; Liang LS; Dai LH; Wang XK
Surg Oncol; 2010 Mar; 19(1):38-45. PubMed ID: 19345093
[TBL] [Abstract][Full Text] [Related]
6. Double-blind randomised placebo-controlled phase III study of an E. coli extract plus 5-fluorouracil versus 5-fluorouracil in patients with advanced colorectal cancer.
Unger C; Häring B; Kruse A; Thumann A; Schneider B; Clemm C; Weber B; Clevert HD; Hockertz S; Kalousek MB
Arzneimittelforschung; 2001; 51(4):332-8. PubMed ID: 11367875
[TBL] [Abstract][Full Text] [Related]
7. [Assessment of the cost of first line chemotherapy in metastatic colorectal cancer. Preliminary results in the FFCD 9601 trial].
Locher C; Auperin A; Boige V; Alzieu L; Pignon JP; Abbas M; Ducreux M
Gastroenterol Clin Biol; 2001; 25(8-9):749-54. PubMed ID: 11598535
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of infusional biomodulated 5-fluorouracil in metastatic colorectal cancer after raltitrexed failure.
Decoster L; Neyns B; Akouaouach H; Fontaine C; Schallier D; De Grève JL
Anticancer Res; 2004; 24(3b):2037-40. PubMed ID: 15274397
[TBL] [Abstract][Full Text] [Related]
9. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
Gamelin E; Delva R; Jacob J; Merrouche Y; Raoul JL; Pezet D; Dorval E; Piot G; Morel A; Boisdron-Celle M
J Clin Oncol; 2008 May; 26(13):2099-105. PubMed ID: 18445839
[TBL] [Abstract][Full Text] [Related]
10. Phase I, pharmacokinetic, and bone marrow drug-level studies of tri-monthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers.
Ho YF; Lu WC; Chen RR; Cheng AL; Yeh KH
Anticancer Drugs; 2011 Mar; 22(3):290-8. PubMed ID: 21150775
[TBL] [Abstract][Full Text] [Related]
11. Impact of uracil/tegafur plus oral calcium folinate on resource utilization.
Ollendorf D
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):42-3. PubMed ID: 10442359
[TBL] [Abstract][Full Text] [Related]
12. DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity.
Rumiato E; Boldrin E; Amadori A; Saggioro D
Cancer Chemother Pharmacol; 2013 Aug; 72(2):483-8. PubMed ID: 23760813
[TBL] [Abstract][Full Text] [Related]
13. [Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
Coursier S; Martelet S; Guillermet A; Emptoz J; Villier C; Bontemps H
Gastroenterol Clin Biol; 2010 Mar; 34(3):218-23. PubMed ID: 20219304
[TBL] [Abstract][Full Text] [Related]
14. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.
Chiara S; Nobile MT; Vincenti M; Lionetto R; Gozza A; Barzacchi MC; Sanguineti O; Repetto L; Rosso R
Cancer Chemother Pharmacol; 1998; 42(4):336-40. PubMed ID: 9744780
[TBL] [Abstract][Full Text] [Related]
15. Advanced colorectal cancer: quality of life and toxicity in patients after weekly 24-hour continuous infusions of biomodulated 5-fluorouracil.
Bogliolo G; Pannacciulli I; Desalvo L; Barsotti B; Lerza R; Mencoboni M; Arboscello E
Anticancer Res; 2000; 20(1B):501-4. PubMed ID: 10769713
[TBL] [Abstract][Full Text] [Related]
16. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
[TBL] [Abstract][Full Text] [Related]
17. 5-FU-induced peripheral neuropathy: a rare complication of a well-known drug.
van Laarhoven HW; Verstappen CC; Beex LV; Kappelle AC; Punt CJ
Anticancer Res; 2003; 23(1B):647-8. PubMed ID: 12680161
[TBL] [Abstract][Full Text] [Related]
18. Oral status in patients receiving 5-fluorouracil for colorectal cancer.
Djuric M; Cakic S; Hadzi-Mihailovic M; Petrovic D; Jankovic L
J BUON; 2010; 15(3):475-9. PubMed ID: 20941813
[TBL] [Abstract][Full Text] [Related]
19. Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients.
Teh LK; Hamzah S; Hashim H; Bannur Z; Zakaria ZA; Hasbullani Z; Shia JK; Fijeraid H; Md Nor A; Zailani M; Ramasamy P; Ngow H; Sood S; Salleh MZ
Ther Drug Monit; 2013 Oct; 35(5):624-30. PubMed ID: 23942539
[TBL] [Abstract][Full Text] [Related]
20. Costs associated with capecitabine or 5-fluorouracil monotherapy after surgical resection in patients with colorectal cancer.
Chu E; Shi N; Wei W; Bendell JC; Cartwright T
Oncology; 2009; 77(3-4):244-53. PubMed ID: 19738390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
